Rosetta Genomics (OTCMKTS:ROSGQ – Get Rating) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Earnings and Valuation

This table compares Rosetta Genomics and Mirum Pharmaceuticals' top-line revenue, earnings per share and valuation.

Rosetta Genomics has higher earnings, but lower revenue than Mirum Pharmaceuticals.

Institutional and Insider Ownership

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Rosetta Genomics and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Mirum Pharmaceuticals has a consensus price target of $54.20, indicating a potential upside of 203.30%.

Risk and Volatility

Rosetta Genomics has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Profitability

This table compares Rosetta Genomics and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Mirum Pharmaceuticals beats Rosetta Genomics on 6 of the 9 factors compared between the two stocks.

About Rosetta Genomics

(Get Rating)

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

About Mirum Pharmaceuticals

(Get Rating)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.